Alpine Immune Sciences Inc ALPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALPN is a good fit for your portfolio.
News
-
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
-
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
-
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
-
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
-
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
-
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
-
Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
Trading Information
- Previous Close Price
- $64.43
- Day Range
- $64.40–64.55
- 52-Week Range
- $6.71–64.57
- Bid/Ask
- $64.53 / $64.50
- Market Cap
- $4.23 Bil
- Volume/Avg
- 4.0 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 54.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 142
Comparables
Valuation
|
Metric
|
ALPN
|
ALLK
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 11.86 | 0.55 | 2.99 |
Price/Sales | 54.72 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALPN
|
ALLK
|
CELC
|
|---|---|---|---|
Quick Ratio | 7.82 | 8.27 | 12.78 |
Current Ratio | 7.86 | 9.31 | 13.43 |
Interest Coverage | −447.30 | — | −12.43 |
Quick Ratio
ALPN
ALLK
CELC
Profitability
|
Metric
|
ALPN
|
ALLK
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −8.37% | −45.63% | −35.57% |
Return on Equity (Normalized) | −11.81% | −58.46% | −49.08% |
Return on Invested Capital (Normalized) | −15.53% | −53.25% | −39.21% |
Return on Assets
ALPN
ALLK
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xlltfxhqv | Zxfr | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Glstqyt | Ctgyrn | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nkytjyxp | Kwlnklj | $98.1 Bil | |
MRNA
| Moderna Inc | Jkgzdzcw | Cprb | $39.1 Bil | |
ARGX
| argenx SE ADR | Mrtgmbrm | Prm | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vbsjfrlvz | Fbp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qzpgyyc | Xjjkqcr | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Khfmmrbx | Gfkss | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sbrlfbbdl | Hqxcd | $12.5 Bil | |
INCY
| Incyte Corp | Fjggdmy | Fgyrnj | $11.9 Bil |